UniQure, Syndax, Erasca Drawing Fresh Analyst Interest
Three clinical-stage biotechs—UniQure, Syndax, and Erasca—are catching analyst attention ahead of key catalysts, with...
Combining the ladder with index funds adds diversification and steadier cash flow, helping manage sequence of return risk over retirement.
28,657 articlesThree clinical-stage biotechs—UniQure, Syndax, and Erasca—are catching analyst attention ahead of key catalysts, with...
A Qatar-linked LNG carrier crossed Hormuz, the first export through the strait since the war intensified. The move co...
A sudden rise in sweetgreen stock often stirs chatter among traders and fans alike. This article explains the common ...
With the 2026 World Cup in North America on the horizon, per-player earnings from prize money could swing widely depe...
A former Central Colorado parcel near Salida is being developed into a 55-acre, 106-home 3D-printed community, testin...
RZC Investments, the Walton family–funded private equity arm, has paused new investments while it reevaluates its fun...
A niche AI hardware stock is drawing investors as hyperscale data centers surge. Analysts say this stock could easies...
A quiet day on the stock market today turned volatile for Boston Scientific after it reaffirmed full-year growth guid...
A recent insider move at Precigen has many investors asking if a CFO’s share sale signals trouble. This deep-dive bre...
A top Wall Street firm is offering interns as much as $8,600 per week for a 10-week program, a level that dwarfs typi...
Nvidia has committed $2 billion to Nebius Group, accelerating Nebius’s role in the neocloud era. The move includes ea...
Circle’s ARC presale unlocks a $3 billion fully diluted valuation and signals a broader push into institutional finan...